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Evidence-based medicine is recognised 
as the way of ensuring individual patients 
receive the correct diagnosis and treatment 
and that health systems ensure that appro-
priate treatments are provided to communi-
ties. Evidence-based medicine is especially 
important in children where many medicines 
are used in an off-label manner. Evidence-
based medicine should result in the more 
rational use of medicines in children.1 
Medical journals provide researchers with a 
location for their research. Peer review along-
side editorial input is used in order to ensure 
that researchers’ findings are presented and 
interpreted objectively. This is essential for the 
generation of objective evidence. BMJ Paediat-
rics Open ensures that the peer review process 
is transparent by publishing the reviewers’ 
names, their comments and previous versions 
of the articles. All articles alongside the peer 
review comments are available to both health 
professionals and the public, free of charge. 
We recognise that not all individuals have 
access to the internet and that in many low 
and lower middle-income countries internet 
availability for health professionals and 
researchers is often intermittent or difficult 
to access.
Data sharing—the provision of the orig-
inal research data for each scientific study 
is not a new idea, but is increasingly being 
recognised as being important.2 Researchers 
involved in systematic reviews are well aware 
that many scientific papers do not adequately 
explain and present all their findings. 
Systematic reviews are an important step in 
drawing up evidence-based guidelines. It is 
well recognised that adverse drug reactions 
are inadequately reported in clinical trials. 
This is especially so in paediatric patients.3 
Additionally, clinical trials involving chil-
dren and adults do not always present the 
paediatric data separately and this is disad-
vantageous to the paediatric population. 
In a systematic review of randomised clin-
ical trials of antiepileptic drugs in children, 
29 trials involved children and adults.3 
However, only 10 stated the actual number 
of children recruited and only 3 analysed 
the paediatric patients separately. Consoli-
dated Standards of Reporting Trials guide-
lines have helped to improve the reporting 
of clinical trials. They do not however insist 
on the separate presentation and analysis 
of different population subgroups such as 
children. Such information should always 
be included in the paper. The provision of 
the original data will allow investigators to 
access this information.
There have also been cases where clin-
ical trial data have been misinterpreted and 
subsequent reanalysis of the original data 
finds different findings. An example of this is 
the reanalysis of trial data for paroxetine in 
the treatment of major depression in adoles-
cents.4 The original trial was published in 
2001 and suggested that paroxetine was effec-
tive in the treatment of adolescent major 
depression.5 An independent reanalysis of 
the data published in 2015 found no evidence 
of efficacy.4 Authors often have preconceived 
ideas about efficacy and safety and will over-
state findings to try and ensure both publi-
cation and impact. The provision of original 
data will allow reanalysis to ensure that the 
interpretation by the authors is correct. A 
gap of 14 years is unacceptable, both scien-
tifically and ethically. The young people who 
participated in the original trial did so to help 
ensure others received the most beneficial 
treatment.
There are also other examples where the 
interpretation of data varies. This results in 
guidelines which differ in their recommen-
dations. There are significant differences 
in the recommendations for the diagnosis 
and management of asthma between the 
National Institute for Health and Care 
Excellence guideline and the collaborative 
guideline from the British Thoracic Society 
and the Scottish Intercollegiate Guideline 
Network.6 Similarly, different countries have 
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different guidelines for eating disorders.7 Recently a 
Cochrane review on human papillomavirus vaccine8 
was criticised for its interpretation of the data.9 
These examples show that the interpretation of data 
is complex, and researchers and health professionals 
need access to original data to ensure patients receive 
optimal treatment.
We are therefore strongly encouraging authors to 
ensure that the data on which their research paper is 
based are made available. Details of what data should be 
stored and how to store it are available in our instruc-
tions to authors. In brief data must be anonymised and 
provided in sufficient detail to allow others to reanalyse 
the data and confirm the author’s findings. There are 
well-established controlled access repositories where 
researchers can deposit data.
For clinical trials, data must be made available on 
reasonable request. Individuals requesting the rele-
vant data need to provide a detailed protocol for their 
proposed study and also to consider inviting the orig-
inal authors to participate in the reanalysis. Guidance 
regarding data from clinical trials has been previously 
published and authors should refer to this article.10
For clinical trials that begin enrolling children on 
or after 1 January 2019, a data-sharing plan must be 
included alongside trial registration. This will result in 
compliance with the International Committee of Medical 
Journal Editors recommendations.11
We are confident that data sharing will become readily 
accepted by the research community and hopefully also 
result in greater collaboration between researchers. It 
should also ensure that all research becomes publicly 
available and that children of all ages receive the best 
possible management and treatment.
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